Targeting key steps in metastatic tumour progression.
The key determinants of tumour progression and discriminators of benign and malignant lesions include neoangiogenesis (the induction of a new blood supply) and the capacity of malignant cells to invade and metastasise. It is now recognized that these processes can be co-ordinately regulated by the activity of specific genes -- often distinct from those involved in early oncogenesis -- and involve common signalling pathways. Cell motility and chemotaxis (the ability to respond to gradients of chemoattractants) are implicated in both tumour-cell invasion and response of activated endothelial cells to angiogenic cytokines, and provide interesting and novel points for therapeutic intervention.
Eccles
Suzanne A
SA
Tumour Biology and Metastasis, Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, McElwain Laboratories, Cotswold Road, Belmont, Sutton, Surrey, SM2 5NG, UK. sue.eccles@icr.ac.uk
D000818:Animals; D002465:Cell Movement / Q000502:physiology; D018925:Chemokines / Q000378:metabolism; D006801:Humans; D000860:Hypoxia / Q000378:metabolism; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic / Q000378:metabolism*; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology
D018925:Chemokines; D043562:Receptors, G-Protein-Coupled; D020794:Receptor Protein-Tyrosine Kinases